{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:18:39Z","timestamp":1784791119765,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00108-026-02154-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:53:29Z","timestamp":1784112809000},"page":"869-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuigkeiten aus Endokrinologie\/Diabetologie","New developments in endocrinology\/diabetology"],"prefix":"10.1007","volume":"67","author":[{"given":"Matthias","family":"Bl\u00fcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2154_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-026-02094-5","author":"A Mathew","year":"2026","unstructured":"Mathew\u00a0A, Sch\u00f6bel\u00a0C, Sauer\u00a0CM (2026) Digital transformation in endocrinology\/diabetology, pneumology, and hematology\/oncology: Where do we stand today - and what lies ahead? Inn Med. https:\/\/doi.org\/10.1007\/s00108-026-02094-5","journal-title":"Die Innere Medizin (Heidelberg)"},{"issue":"Suppl","key":"2154_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00108-026-02093-6","volume":"67","author":"G Ertl","year":"2026","unstructured":"Ertl\u00a0G, Sauerbruch\u00a0T, F\u00fchrer-Sakel\u00a0D (2026) Pr\u00e4vention und Vorsorge. Inn Med 67(Suppl):1\u201310. https:\/\/doi.org\/10.1007\/s00108-026-02093-6","journal-title":"Die Innere Medizin (Heidelberg)"},{"issue":"Suppl 1","key":"2154_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00108-026-02094-5","volume":"67","author":"M Pfohl","year":"2026","unstructured":"Pfohl\u00a0M, Reincke\u00a0M, Seufert\u00a0J et\u00a0al (2026) Pr\u00e4ventionsfelder der Endokrinologie\/ Diabetologie \u2013 \u201eThe Big Five\u201c. Inn Med 67(Suppl 1):30\u201334. https:\/\/doi.org\/10.1007\/s00108-026-02094-5","journal-title":"Die Innere Medizin (Heidelberg)"},{"key":"2154_CR4","volume":"10","author":"A Starker","year":"2025","unstructured":"Starker\u00a0A, Schienkiewitz\u00a0A, Damerow\u00a0S, Kuhnert\u00a0R (2025) Prevalence of obesity and smoking among adults in Germany - trends from 2003 to 2023. J\u00a0Health Monit 10:e13038","journal-title":"J Health Monit"},{"key":"2154_CR5","unstructured":"https:\/\/icd.who.int. Letzter Zugriff: 22. Febr. 2026"},{"issue":"Suppl 2","key":"2154_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","volume":"27","author":"M Bl\u00fcher","year":"2025","unstructured":"Bl\u00fcher\u00a0M (2025) An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab 27(Suppl 2):3\u201319","journal-title":"Diabetes Obes Metab"},{"key":"2154_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino\u00a0F, Cummings\u00a0DE, Eckel\u00a0RH, Cohen\u00a0RV, Wilding\u00a0JPH, Brown\u00a0WA, Stanford\u00a0FC, Batterham\u00a0RL, Farooqi\u00a0IS, Farpour-Lambert\u00a0NJ, le Roux\u00a0CW, Sattar\u00a0N, Baur\u00a0LA, Morrison\u00a0KM, Misra\u00a0A, Kadowaki\u00a0T, Tham\u00a0KW, Sumithran\u00a0P, Garvey\u00a0WT, Kirwan\u00a0JP, Fern\u00e1ndez-Real\u00a0JM, Corkey\u00a0BE, Toplak\u00a0H, Kokkinos\u00a0A, Kushner\u00a0RF, Branca\u00a0F, Valabhji\u00a0J, Bl\u00fcher\u00a0M, Bornstein\u00a0SR, Grill\u00a0HJ, Ravussin\u00a0E, Gregg\u00a0E, Al Busaidi\u00a0NB, Alfaris\u00a0NF, Al Ozairi\u00a0E, Carlsson\u00a0LMS, Cl\u00e9ment\u00a0K, Despr\u00e9s\u00a0JP, Dixon\u00a0JB, Galea\u00a0G, Kaplan\u00a0LM, Laferr\u00e8re\u00a0B, Laville\u00a0M, Lim\u00a0S, Luna Fuentes\u00a0JR, Mooney\u00a0VM, Nadglowski\u00a0J Jr, Urudinachi\u00a0A, Olszanecka-Glinianowicz\u00a0M, Pan\u00a0A, Pattou\u00a0F, Schauer\u00a0PR, Tsch\u00f6p\u00a0MH, van der Merwe\u00a0MT, Vettor\u00a0R, Mingrone\u00a0G (2025) Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 13:221\u2013262","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2154_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto\u00a0L, Dicker\u00a0D, Fr\u00fchbeck\u00a0G, Halford\u00a0JCG, Sbraccia\u00a0P, Yumuk\u00a0V, Goossens\u00a0GH (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30:2395\u20132399","journal-title":"Nat Med"},{"key":"2154_CR9","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","volume":"45","author":"KC Koskinas","year":"2024","unstructured":"Koskinas\u00a0KC, Van Craenenbroeck\u00a0EM, Antoniades\u00a0C, Bl\u00fcher\u00a0M, Gorter\u00a0TM, Hanssen\u00a0H, Marx\u00a0N, McDonagh\u00a0TA, Mingrone\u00a0G, Rosengren\u00a0A, Prescott\u00a0EB, ESC Scientific Document Group (2024) Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J 45:4063\u20134098","journal-title":"Eur Heart J"},{"key":"2154_CR10","unstructured":"Deutsche Adipositas-Gesellschaft (DAG) e.\u202fV. Leitlinie Pr\u00e4vention und Therapie der Adipositas. Letzter Zugriff: 20. Febr. 2026 unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/050-001"},{"key":"2154_CR11","unstructured":"https:\/\/www.who.int\/news\/item\/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity. Letzter Zugriff: 20. Febr. 2026"},{"key":"2154_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie\u00a0Y, Choi\u00a0T, Al-Aly\u00a0Z (2025) Mapping the effectiveness and risks of GLP\u20111 receptor agonists. Nat Med 31:951\u2013962","journal-title":"Nat Med"},{"key":"2154_CR13","doi-asserted-by":"crossref","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M (2026) Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet S0140\u20136736(25)02105\u20111.","DOI":"10.1016\/S0140-6736(25)02105-1"},{"key":"2154_CR14","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls\u00a0SJ, Pavo\u00a0I, Bhatt\u00a0DL, Buse\u00a0JB, Del Prato\u00a0S, Kahn\u00a0SE, Lincoff\u00a0AM, McGuire\u00a0DK, Miller\u00a0D, Nauck\u00a0MA, Nishiyama\u00a0H, Nissen\u00a0SE, Sattar\u00a0N, Weerakkody\u00a0G, Wiese\u00a0RJ, Zinman\u00a0B, Zoungas\u00a0S, Basile\u00a0J, Davies\u00a0MJ, Giorgino\u00a0F, Kellerer\u00a0M, Ji\u00a0L, Varkonyi\u00a0T, Menon\u00a0V, Broder\u00a0JC, Herschtal\u00a0A, D\u2019Alessio\u00a0D, SURPASS-CVOT Investigators (2025) Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 393:2409\u20132420","journal-title":"N Engl J Med"},{"key":"2154_CR15","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"Fassnacht\u00a0M, Tsagarakis\u00a0S, Terzolo\u00a0M, Tabarin\u00a0A, Sahdev\u00a0A, Newell-Price\u00a0J, Pelsma\u00a0I, Marina\u00a0L, Lorenz\u00a0K, Bancos\u00a0I, Arlt\u00a0W, Dekkers\u00a0OM (2023) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 189:G1\u2013G42","journal-title":"Eur J Endocrinol"},{"key":"2154_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S2213-8587(25)00062-2","volume":"13","author":"A Tabarin","year":"2025","unstructured":"Tabarin\u00a0A, Espiard\u00a0S, Deutschbein\u00a0T, Amar\u00a0L, Vezzossi\u00a0D, Di Dalmazi\u00a0G, Reznik\u00a0Y, Young\u00a0J, Desailloud\u00a0R, Goichot\u00a0B, Drui\u00a0D, Assie\u00a0G, Lefebvre\u00a0H, Mai\u00a0K, Castinetti\u00a0F, Laboureau\u00a0S, Terzolo\u00a0M, Ferriere\u00a0A, Georget\u00a0A, Frison\u00a0E, Vantyghem\u00a0MC, Fassnacht\u00a0M, Gosse\u00a0P, Collaborators C (2025) Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol 13:580\u2013590","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2154_CR17","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler\u00a0GK, Stowasser\u00a0M, Correa\u00a0RR, Khan\u00a0N, Kline\u00a0G, McGowan\u00a0MJ, Mulatero\u00a0P, Murad\u00a0MH, Touyz\u00a0RM, Vaidya\u00a0A, Williams\u00a0TA, Yang\u00a0J, Young\u00a0WF, Zennaro\u00a0MC, Brito\u00a0JP (2025) Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J\u00a0Clin Endocrinol Metab 110(9):2453\u20132495","journal-title":"J Clin Endocrinol Metab"},{"key":"2154_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen\u00a0JB, Cohen\u00a0DL, Herman\u00a0DS, Leppert\u00a0JT, Byrd\u00a0JB, Bhalla\u00a0V (2021) Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Ann Intern Med 174:289\u2013297","journal-title":"Ann Intern Med"},{"key":"2154_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu\u00a0J, Zhou\u00a0Q, Sun\u00a0Y, Feng\u00a0Z, Yang\u00a0J, He\u00a0W, Song\u00a0Y, Wang\u00a0Y, Chen\u00a0X, Shen\u00a0H, Jing\u00a0Y, Yang\u00a0S, Li\u00a0Q (2025) Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A\u00a0Pilot Randomized Controlled Trial. Circulation 151:196\u2013198","journal-title":"Circulation"},{"key":"2154_CR20","doi-asserted-by":"publisher","first-page":"K50","DOI":"10.1093\/ejendo\/lvaf099","volume":"192","author":"T Uslar","year":"2025","unstructured":"Uslar\u00a0T, Sanfuentes\u00a0B, Munoz\u00a0I, Vaidya\u00a0A, Baudrand\u00a0R (2025) Real-world outcomes of finerenone in primary aldosteronism. Eur J Endocrinol 192:K50\u2013K53","journal-title":"Eur J Endocrinol"},{"key":"2154_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu\u00a0AF, Freeman\u00a0MW, Bancos\u00a0I, Ben-Shlomo\u00a0A, Hamidi\u00a0O, Hamrahian\u00a0AH, Huang\u00a0W, Kirschner\u00a0LS, Sam\u00a0R, Mallappa\u00a0A, Tuyishimire\u00a0B, Lihn\u00a0AS, Perl\u00a0S, Brown\u00a0MJ, Group\u00a0SI (2025) Phase 2a Study of Baxdrostat in Primary Aldosteronism. N Engl J Med 393:515\u2013518","journal-title":"N Engl J Med"},{"key":"2154_CR22","unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/schilddruesenkarzinom"},{"issue":"5","key":"2154_CR23","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0067","volume":"12","author":"C Durante","year":"2023","unstructured":"Durante\u00a0C, Heged\u00fcs\u00a0L, Czarniecka\u00a0A, Paschke\u00a0R, Russ\u00a0G, Schmitt\u00a0F, Soares\u00a0P, Solymosi\u00a0T, Papini\u00a0E (2023) 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J 12(5):e230067. https:\/\/doi.org\/10.1530\/ETJ-23-0067","journal-title":"Eur Thyroid J"},{"issue":"4","key":"2154_CR24","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0024","volume":"14","author":"A Ry\u0161ka","year":"2025","unstructured":"Ry\u0161ka\u00a0A, Capdevila\u00a0J, Dettmer\u00a0MS, Elisei\u00a0R, F\u00fchrer\u00a0D, Hadoux\u00a0J, Jarz\u0105b\u00a0B, Locati\u00a0LD, Newbold\u00a0K, Tallini\u00a0G, Uccella\u00a0S, Wirth\u00a0L, Singh\u00a0R, Simon\u00a0IM, Camacho\u00a0P, Fugazzola\u00a0L (2025) Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus. Eur Thyroid J 14(4):e250024. https:\/\/doi.org\/10.1530\/ETJ-25-0024","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2154_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-21-0046","volume":"11","author":"F Pacini","year":"2022","unstructured":"Pacini\u00a0F, Fuhrer\u00a0D, Elisei\u00a0R, Handkiewicz-Junak\u00a0D, Leboulleux\u00a0S, Luster\u00a0M, Schlumberger\u00a0M, Smit\u00a0JW (2022) 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 11(1):e210046. https:\/\/doi.org\/10.1530\/ETJ-21-0046","journal-title":"Eur Thyroid J"},{"issue":"8","key":"2154_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel\u00a0MD, Sosa\u00a0JA, Baloch\u00a0Z, Bischoff\u00a0L, Bloom\u00a0G, Brent\u00a0GA, Brock\u00a0PL, Chou\u00a0R, Flavell\u00a0RR, Goldner\u00a0W, Grubbs\u00a0EG, Haymart\u00a0M, Larson\u00a0SM, Leung\u00a0AM, Osborne\u00a0JR, Ridge\u00a0JA, Robinson\u00a0B, Steward\u00a0DL, Tufano\u00a0RP, Wirth\u00a0LJ (2025) 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid 35(8):841\u2013985. https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"},{"issue":"10498","key":"2154_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0140-6736(25)00781-0","volume":"406","author":"DM Hartl","year":"2025","unstructured":"Hartl\u00a0DM (2025) Practice-changing evidence for low-risk differentiated thyroid cancer. Lancet 406(10498):5\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(25)00781-0","journal-title":"Lancet"},{"issue":"1","key":"2154_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2213-8587(24)00276-6","volume":"13","author":"S Leboulleux","year":"2025","unstructured":"Leboulleux\u00a0S, Bournaud\u00a0C, Chougnet\u00a0CN, Lamartina\u00a0L, Zerdoud\u00a0S, Do Cao\u00a0C, Catargi\u00a0B, Dygai\u00a0I, Kelly\u00a0A, Barge\u00a0ML, Vera\u00a0P, Rusu\u00a0D, Schneegans\u00a0O, Roux\u00a0J, Raymond\u00a0P, Benisvy\u00a0D, Eberle\u00a0MC, Bidault\u00a0S, Nascimento\u00a0C, Bastie\u00a0D, Giraudet\u00a0AL, Bardet\u00a0S, Le Moullec\u00a0N, Roudaut\u00a0N, Drui\u00a0D, Godbert\u00a0Y, Zalzali\u00a0M, Drutel\u00a0A, Morel\u00a0O, Velayoudom\u00a0FL, Al Ghuzlan\u00a0A, Schlumberger\u00a0M, Buffet\u00a0C, Borget\u00a0I (2025) Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. Lancet Diabetes Endocrinol 13(1):38\u201346. https:\/\/doi.org\/10.1016\/S2213-8587(24)00276-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10498","key":"2154_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0140-6736(25)00629-4","volume":"406","author":"U Mallick","year":"2025","unstructured":"Mallick\u00a0U, Newbold\u00a0K, Beasley\u00a0M, Garcez\u00a0K, Wadsley\u00a0J, Johnson\u00a0SJ, Stephenson\u00a0T, Gaze\u00a0M, Goodman\u00a0A, Jefferies\u00a0S, Sivabalasingham\u00a0S, Slevin\u00a0N, Wilkinson\u00a0DP, Macias-Fernandez\u00a0E, Power\u00a0D, Roques\u00a0T, Speed\u00a0L, Nutting\u00a0C, Mochloulis\u00a0G, Gerrard\u00a0G, Candish\u00a0C, Morgan\u00a0S, Tripathi\u00a0D, Truran\u00a0P, Arthur\u00a0C, Wieczorek\u00a0A, Madhavan\u00a0K, Maclean\u00a0J, Boote\u00a0D, Kim\u00a0D, Pascoe\u00a0A, Pitiyage\u00a0G, Forsyth\u00a0S, Ambrose\u00a0E, Chang\u00a0E, Farnell\u00a0K, Hackshaw\u00a0A (2025) Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial. Lancet 406(10498):52\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(25)00629-4","journal-title":"Lancet"},{"issue":"5","key":"2154_CR30","doi-asserted-by":"publisher","first-page":"e1377","DOI":"10.1210\/clinem\/dgae559","volume":"110","author":"G Grani","year":"2025","unstructured":"Grani\u00a0G, D\u2019Elia\u00a0S, Puxeddu\u00a0E, Morelli\u00a0S, Arvat\u00a0E, Nervo\u00a0A, Spiazzi\u00a0G, Rolli\u00a0N, Zatelli\u00a0MC, Ambrosio\u00a0MR, Ceresini\u00a0G, Marina\u00a0M, Mele\u00a0C, Aimaretti\u00a0G, Santaguida\u00a0MG, Virili\u00a0C, Crescenzi\u00a0A, Palermo\u00a0A, Rossetto Giaccherino\u00a0R, Meomartino\u00a0L, Castagna\u00a0MG, Maino\u00a0F, Trevisan\u00a0M, De Leo\u00a0S, Chiofalo\u00a0MG, Pezzullo\u00a0L, Sparano\u00a0C, Petrone\u00a0L, Di Dalmazi\u00a0G, Napolitano\u00a0G, Tumino\u00a0D, Crocetti\u00a0U, Bertagna\u00a0F, Deandrea\u00a0M, Antonelli\u00a0A, Mian\u00a0C, Carbone\u00a0A, Monti\u00a0S, Porcelli\u00a0T, Brigante\u00a0G, Barbaro\u00a0D, Alf\u00f2\u00a0M, Ferraro Petrillo\u00a0U, Filetti\u00a0S, Durante\u00a0C (2025) Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis. JCEM Case Rep 110(5):e1377\u2013e1384. https:\/\/doi.org\/10.1210\/clinem\/dgae559","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02154-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:53:21Z","timestamp":1784789601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02154-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02154-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Bl\u00fcher, J.\u00a0Bojunga, M.\u00a0Fassnacht und D.\u00a0F\u00fchrer-Sakel erkl\u00e4ren, dass sie sich bei der Erstellung des Beitrages nicht von wirtschaftlichen Interessen leiten lie\u00dfen. Sie legen die folgenden potenziellen Interessenkonflikte offen: M.\u00a0Bl\u00fcher: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit von Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, MSD, Novartis, Novo Nordisk und Sanofi. J.\u00a0Bojunga: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit von AstraZeneca, BMS, Boehringer Ingelheim, IBSA, IPSEN, Lilly, Novartis, Novo Nordisk, MSD, Pfizer, Recordati, Sanofi, Shire. M.\u00a0Fassnacht: Forschungsunterst\u00fctzung von Enterome, HRA Pharma, Lilly, Novartis, MSD, DFG, BMBF, Dt. Krebshilfe, Gemeinsamer Bundesausschuss (G-BA) und Vortragst\u00e4tigkeit bei Boehringer-Ingelheim sowie Beratungst\u00e4tigkeit bei HRA Pharma und Bayer an (jeweils als Dienstauftrag f\u00fcr das Universit\u00e4tsklinikum W\u00fcrzburg). D.\u00a0F\u00fchrer-Sakel: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit von Amgen, IBSA, Ipsen, Lilly, Novartis, Merck, Roche, Sanofi, Theramex und Beratert\u00e4tigkeit f\u00fcr die DKV (als Dienstauftrag f\u00fcr das Universit\u00e4tsklinikum Essen).","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}